Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 12

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

Authors Howell R, Wright AM, Clements JN

Received 20 November 2018

Accepted for publication 12 February 2019

Published 17 April 2019 Volume 2019:12 Pages 505—512

DOI https://doi.org/10.2147/DMSO.S174568

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 3

Editor who approved publication: Dr Konstantinos Tziomalos


Rebecca Howell,1 Adrienne M Wright,1 Jennifer N Clements2

1Presbyterian College School of Pharmacy, Clinton, SC 29325, USA; 2Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC 29325, USA

Abstract: Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of metformin, add-on therapy can be considered if an individual’s glycemic control has not been achieved for hemoglobin A1c, fasting blood glucose levels, and postprandial blood glucose levels. Liraglutide is a potential second-line option for the management of type 2 diabetes mellitus, particularly for those who are or may be at a high risk of cardiovascular disease. It can also be used an add-on therapy for those individuals with established cardiovascular disease. Liraglutide has additional benefits, such as no to minimal risk of hypoglycemia and promotion of weight loss through its mechanism of action. This particular article summarizes evidence on cardiovascular biomarkers and surrogate endpoints, along with macrovascular events, with liraglutide therapy. Overall, liraglutide has extensive cardiovascular evidence based on which it could be used as a desirable agent for glycemic control while lowering the risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization from heart failure.

Keywords: glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, liraglutide, cardiovascular


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]